Don Dizon, MD on Challenges in Collecting Gender Identity and Sexual Orientation Data in Clinical Cancer Research

Currently, it is not known whether cisgender and transgender patients with cancer respond similarly to standard-of-care therapies due to challenges collecting gender identity and sexual orientation data in clinical cancer research.

In an interview with CancerNetwork®, Don Dizon, MD, FACP, FASCO, director of women’s cancers at the Lifespan Cancer Institute, director of medical oncology at Rhode Island Hospital, and professor of medicine at the Warren Alpert Medical School of Brown University in Providence, highlighted challenges with collecting gender identity and sexual orientation data in clinical cancer research. As patients cannot currently be identified based on sexual orientation or gender identity, it is not currently possible to assess outcomes of patients in the Lesbian, Gay, Bisexual, Transgender, and Questioning plus (LGBTQ+) community.


The biggest challenge is that we don’t do it. The problem with that is because LGBTQ+ individuals are not identified as such in our research databases, there’s no way for us to even start examining their outcomes. This is particularly relevant for transgender individuals, in whom gender-affirming hormone therapy is part of their normal lives. These are folks who may or may not have had gender-affirming surgeries. [Seeing] what their experience has been on therapeutic clinical trials is important, especially when you consider, for example, [that] we base so much of the way we dose drugs for toxicity sake on a basic question: Are you male or female? If one was assigned female at birth, but has realized their gender is male, that presents a dilemma. How do you dose this individual safely? We don’t even know the correct answer to that most basic question, but we would want to know what the outcomes were. Does standard therapy work as well in a transgender patient [as] it does in a cisgender patient, for example? These are critical questions, especially as we're trying to achieve equity, not only terms of access, but in terms of outcomes.

Related Videos
Although opioid use guidelines from the Centers for Disease Control exclude patients with cancer, drug screenings are required that could further contribute to racial disparities.
An expert from Dana-Farber Cancer Institute says that policymakers and insurers should take a hard look at policies that restrict opioid use in patients with cancer who are at end of life, especially for underserved communities.
After assessing racial disparities in opioid access in older patients with cancer, an expert from Dana-Farber Cancer Institute speaks to the need for examining younger populations and those with different insurance types.
An expert from Dana-Farber Cancer Institute states that although giving opioids for minor procedures could lead to substance abuse issues, use of the drugs to manage end of life cancer pain should not be up for debate.
An expert from Dana-Farber Cancer Institute discusses data from a study investigating racial inequities in opioid access among patients of cancer near the end of life.
An expert from Dana-Farber Cancer Institute describes several key strategies for mitigating racial disparities in opioid access among patients with cancer near end of life.
It takes a team of physicians from multidisciplinary backgrounds to best manage patients with contralateral breast cancer, according to a Mayo Clinic Expert.
The presence of several risk factors—such as age, race and mutation status—for contralateral breast cancer must be considered when making treatment decisions, according to an expert from the Mayo Clinic.
Recent study findings related to risk factors for developing contralateral breast cancer may better influence treatment decisions between patients and physicians, according to a Mayo Clinic expert.
An expert from the Mayo Clinic discusses findings from a population-based study concerning germline genetic mutations as risk factors of contralateral breast cancer.
Related Content